BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction

Starting soon · Early Phase 1

Conditions studied: Lung Transplant Recipient

In brief

This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.

Key facts

Study ID

NCT07410312

Run by

Northwestern University

People needed

20

Starts

2026-07-01

Expected to finish

2027-12-01

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older.
• Planning to undergo transplantation of the lung.
• Willing and able to read, understand, and be capable of giving informed consent.
• Use of ex vivo lung perfusion (EVLP) prior to lung transplant.

You may not qualify if…

• Previous or current use of IL-1R antagonist drug.
• Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating, such as highly sensitized patients who require additional immunosuppression, multiorgan transplant, and re- transplant.

Where it is running

• Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.